Y Intercept Hong Kong Ltd Acquires New Holdings in Globus Medical, Inc. $GMED

Y Intercept Hong Kong Ltd acquired a new position in Globus Medical, Inc. (NYSE:GMED) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,764 shares of the medical device company’s stock, valued at approximately $1,961,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Advisory Services Network LLC acquired a new position in Globus Medical during the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC lifted its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the period. SBI Securities Co. Ltd. lifted its stake in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares in the last quarter. Finally, Headlands Technologies LLC boosted its holdings in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

GMED stock opened at $76.23 on Thursday. The firm has a market cap of $10.35 billion, a PE ratio of 17.73, a P/E/G ratio of 1.63 and a beta of 0.95. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a 50 day simple moving average of $81.13 and a 200 day simple moving average of $86.97.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 18.38% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on GMED. Stifel Nicolaus cut their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Needham & Company LLC boosted their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. BMO Capital Markets started coverage on Globus Medical in a report on Wednesday. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $105.42.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.